Document Detail


Longitudinal analysis of raltegravir susceptibility and integrase replication capacity of human immunodeficiency virus type 1 during virologic failure.
MedLine Citation:
PMID:  19667293     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
We characterized the raltegravir (RAL) susceptibility and the integrase (IN)-mediated replication capacity (RC) of RAL-resistant human immunodeficiency virus type 1 from two patients experiencing virologic failure during continuous RAL salvage therapy. The following two distinct outcomes were observed: (i) the selective outgrowth of virus with high-level RAL resistance and high IN-mediated RC leading to significant viral load rebound and (ii) the selection of virus with a slight reduction in RAL susceptibility and low IN-mediated RC resulting in sustained low-level viremia.
Authors:
Signe Fransen; Marina Karmochkine; Wei Huang; Laurence Weiss; Christos J Petropoulos; Charlotte Charpentier
Related Documents :
2121033 - Drug prophylaxis for human immunodeficiency virus-infected pregnant women: ethical cons...
7699053 - Length of incubation time for human immunodeficiency virus cultures.
16054723 - Acute gb virus b infection of marmosets is accompanied by mutations in the ns5a protein.
Publication Detail:
Type:  Journal Article     Date:  2009-08-10
Journal Detail:
Title:  Antimicrobial agents and chemotherapy     Volume:  53     ISSN:  1098-6596     ISO Abbreviation:  Antimicrob. Agents Chemother.     Publication Date:  2009 Oct 
Date Detail:
Created Date:  2009-09-22     Completed Date:  2009-12-14     Revised Date:  2013-06-02    
Medline Journal Info:
Nlm Unique ID:  0315061     Medline TA:  Antimicrob Agents Chemother     Country:  United States    
Other Details:
Languages:  eng     Pagination:  4522-4     Citation Subset:  IM    
Affiliation:
Monogram Biosciences, South San Francisco, California, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Cell Line
Drug Resistance, Viral / genetics
HIV Integrase Inhibitors / pharmacology*
HIV-1 / drug effects*,  enzymology
Humans
Pyrrolidinones / pharmacology*
Virus Replication / drug effects
Chemical
Reg. No./Substance:
0/HIV Integrase Inhibitors; 0/Pyrrolidinones; 22VKV8053U/raltegravir
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Examination of potential mechanisms to explain the association between proton pump inhibitors and Cl...
Next Document:  Healthy living is the best revenge: findings from the European Prospective Investigation Into Cancer...